Company news

Rhythm Biosciences Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Rhythm Receives $2.7m R&D Tax Incentive

October 20, 2022

Director Share Sale To Institutional Funds Manager

September 8, 2022

RHY Advances Platform Expansion with Other Cancers

July 18, 2022

Application for quotation of securities - RHY

June 19, 2022

Completion of Final TGA Submission Step to Approve ColoSTAT

May 11, 2022

Rhythm Closes Final Clinical Trial Site

May 3, 2022

Appendix 4C - quarterly

April 27, 2022

Rhythm Biosciences: RHY Presentation at PAC Partners Healthcare Conference

April 5, 2022

Rhythm Biosciences - Investor Presentation

April 4, 2022

Study 7 Confirms ColoSTAT Meets Primary Endpoint

April 3, 2022

S&P DJI Announces March 2022 Quarterly Rebalance

March 4, 2022

Rhythm Biosciences - Investor Webinar Presentation

March 1, 2022

Appendix 4D and Half Yearly Report and Accounts

February 24, 2022

Rhythm Maintains Ongoing ISO13485 Certification

February 14, 2022

Placement of $6.5m to Global Institutional Funds Manager

January 5, 2022

RHY Platform Technology Targets Five Cancers

December 13, 2021

Board and Management Restructure

November 30, 2021

CE Mark Granted for ColoSTAT

November 29, 2021

Change of Director's Interest Notice x 4

November 25, 2021

Application for quotation of securities - RHY

November 12, 2021

RHY - Institutional Investor Presentation

November 9, 2021

ColoSTAT Test Kits Deliver Consistent, High Accuracy Results

October 20, 2021

Rhythm Receives $2.4m R&D Tax Incentive

October 4, 2021

Rhythm Completes Recruitment for Clinical Trial (Study 7)

September 21, 2021

TGA Accepts Initial Regulatory Documentation

September 14, 2021

Rhythm Completes Strongly Oversubscribed $4.3M Rights Issue

September 7, 2021

Initial TGA Regulatory Documentation Submitted

August 18, 2021

Non Renounceable pro rata offer - Completion of despatch

August 9, 2021

Rights Issue Investor Presentation

July 30, 2021

Non renouneable rights issue prospectus

July 29, 2021

Rhythm Establishes US Entity To Drive US Expansion Strategy

July 14, 2021

Rhythm to Present at MST Access Investor Conference

June 17, 2021

RHY adds Sonic Clinical Services to ColoSTAT Clinical Trial

June 15, 2021

FY22 Strategic Update

May 17, 2021

Rhythm Betters ColoSTAT Results

May 5, 2021

Rhythm Extends ColoSTAT Clinical Trial to Western Australia

April 12, 2021

Rhythm Retains ISO13485 Certification

March 30, 2021

Study 6 Successfully Concluded - Exceptional Results

March 15, 2021

Rhythm Expands ColoSTAT Clinical Trial To Tenth Site

February 10, 2021

Initial Manufacturing of ColoSTAT Test-Kits Complete

January 19, 2021

Rhythm Advances ColoSTAT Study 7

January 18, 2021

Investor Presentation - December 2020

December 20, 2020

Rhythm Secures US Patent - Strengthens Global Footprint

December 16, 2020

Rhythm Appoints Global Manufacturer for ColoSTAT

December 1, 2020

AGM Presentation - November 2020

November 17, 2020

ColoSTAT Prototype Complete, Outperforms FIT

November 11, 2020

Ethics Approval Received, New Clinical Trial Site Added

October 26, 2020

Rhythm Receives $1.1m R&D Tax Incentive

October 15, 2020

Final Two Adjunct Biomarkers Technically Validated

September 28, 2020

New Clinical Trial Site Contracted and Recruiting

September 22, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 46 decks. Every deck is listed under its year.